Our Story

Chun-Nan Chen founded Single Cell Technology in 2008 with partners Jim Bowlby and Rich Jorgensen. We named our technology after the Greek word atheneum, meaning an institute for scientific learning. AbTheneum™ technology was independently developed by merging innovations and ideas from microfabrication, semiconductor processing, molecular biology, bioinformatics, cell biology, and immunology. SCT holds numerous patents on its core technology in the US and worldwide. SCT's team worked with pharmaceutical companies and CROs to validate AbTheneum™ and demonstrated end-to-end capabilities for parallel sequencing of cells with their respective secreted antibodies in 2015.

Since the breakthrough, SCT has run numerous discovery campaigns with partners, sequencing millions of cells in the process. SCT also continues to innovate and add features to AbTheneum™.

Our Goals

We are passionate about using our technology. We feel that we have built an engine that can be utilized for the good of human health. AbTheneum™ data output has the power to show previously unknown insights from the immune system. In an age of Big Data, SCT's goal is to use AbTheneum™ data to drive antibody discovery and to a new paradigm.


Mark J. Shlomchik, M.D., Ph.D.

Chair of Department of Immunology, University of Pittsburgh School of Medicine

George Church, Ph.D.

Professor of Genetics, Harvard Medical School and Director of the Center for Computational Genetics

Yen-Ming Hsu, Ph.D.

CEO, AB Biosciences, Inc.
Boston, Massachusetts.